Below are the most recent publications written about "Dopamine Agonists" by people in Profiles.
-
Pringsheim T, Day GS, Smith DB, Rae-Grant A, Licking N, Armstrong MJ, de Bie RMA, Roze E, Miyasaki JM, Hauser RA, Espay AJ, Martello JP, Gurwell JA, Billinghurst L, Sullivan K, Fitts MS, Cothros N, Hall DA, Rafferty M, Hagerbrant L, Hastings T, O'Brien MD, Silsbee H, Gronseth G, Lang AE. Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee. Neurology. 2021 11 16; 97(20):942-957.
-
Manning PJ, Grattan D, Merriman T, Manning T, Williams S, Sutherland W. Pharmaceutical interventions for weight-loss maintenance: no effect from cabergoline. Int J Obes (Lond). 2018 11; 42(11):1871-1879.
-
Tanaka S, Link MJ, Brown PD, Stafford SL, Young WF, Pollock BE. Gamma knife radiosurgery for patients with prolactin-secreting pituitary adenomas. World Neurosurg. 2010 Jul; 74(1):147-52.
-
Williams SN, Undieh AS. Brain-derived neurotrophic factor signaling modulates cocaine induction of reward-associated ultrasonic vocalization in rats. J Pharmacol Exp Ther. 2010 Feb; 332(2):463-8.
-
Brennan JA, Graf R, Grauer SM, Navarra RL, Pulicicchio CM, Hughes ZA, Lin Q, Wantuch C, Rosenzweig-Lipson S, Pruthi F, Lai M, Smith D, Goutier W, van de Neut M, Robichaud AJ, Rotella D, Feenstra RW, Kruse C, Broqua P, Beyer CE, McCreary AC, Pausch MH, Marquis KL. WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity. J Pharmacol Exp Ther. 2010 Jan; 332(1):190-201.
-
Meldrum DR, Chang RJ, de Ziegler D, Schoolcraft WB, Scott RT, Pellicer A. Adjuncts for ovarian stimulation: when do we adopt "orphan indications" for approved drugs? Fertil Steril. 2009 Jul; 92(1):13-8.
-
Williams SN, Undieh AS. Dopamine D1-like receptor activation induces brain-derived neurotrophic factor protein expression. Neuroreport. 2009 Apr 22; 20(6):606-10.
-
Sahu A, Tyeryar KR, Vongtau HO, Sibley DR, Undieh AS. D5 dopamine receptors are required for dopaminergic activation of phospholipase C. Mol Pharmacol. 2009 Mar; 75(3):447-53.
-
Whyte J, Vaccaro M, Grieb-Neff P, Hart T, Polansky M, Coslett HB. The effects of bromocriptine on attention deficits after traumatic brain injury: a placebo-controlled pilot study. Am J Phys Med Rehabil. 2008 Feb; 87(2):85-99.
-
Ahmed MR, Bychkov E, Gurevich VV, Benovic JL, Gurevich EV. Altered expression and subcellular distribution of GRK subtypes in the dopamine-depleted rat basal ganglia is not normalized by l-DOPA treatment. J Neurochem. 2008 Mar; 104(6):1622-36.